CN105530934A - 组合药物疗法 - Google Patents

组合药物疗法 Download PDF

Info

Publication number
CN105530934A
CN105530934A CN201480051583.9A CN201480051583A CN105530934A CN 105530934 A CN105530934 A CN 105530934A CN 201480051583 A CN201480051583 A CN 201480051583A CN 105530934 A CN105530934 A CN 105530934A
Authority
CN
China
Prior art keywords
cancer
methyl
combination product
compound
trifluoromethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201480051583.9A
Other languages
English (en)
Chinese (zh)
Inventor
J.格雷肖克
K.E.巴赫曼
S.C.布莱克曼
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline LLC
Original Assignee
GlaxoSmithKline LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline LLC filed Critical GlaxoSmithKline LLC
Publication of CN105530934A publication Critical patent/CN105530934A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201480051583.9A 2013-09-19 2014-09-16 组合药物疗法 Pending CN105530934A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361879895P 2013-09-19 2013-09-19
US61/879895 2013-09-19
PCT/US2014/055816 WO2015042029A1 (en) 2013-09-19 2014-09-16 Combination drug therapy

Publications (1)

Publication Number Publication Date
CN105530934A true CN105530934A (zh) 2016-04-27

Family

ID=52689320

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201480051583.9A Pending CN105530934A (zh) 2013-09-19 2014-09-16 组合药物疗法

Country Status (10)

Country Link
US (1) US20160228446A1 (https=)
EP (1) EP3046556A4 (https=)
JP (3) JP6346944B2 (https=)
KR (1) KR20160055911A (https=)
CN (1) CN105530934A (https=)
AU (1) AU2014321456B2 (https=)
BR (1) BR112016005000A8 (https=)
CA (1) CA2921156A1 (https=)
RU (1) RU2016110546A (https=)
WO (1) WO2015042029A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014321456B2 (en) * 2013-09-19 2018-05-24 Glaxosmithkline Llc Combination drug therapy
US10206949B2 (en) 2015-09-21 2019-02-19 Ofer Agam Composition that relieves heartburn, GERD and hangovers
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
US20210393651A1 (en) * 2018-11-09 2021-12-23 Dana-Farber Cancer Institute, Inc. Targeting the oncogenic transcription factor stat5 with mineralocorticoid analogues

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090175868A1 (en) * 2006-02-03 2009-07-09 Ludwig Dale L IGF-IR antagonists as adjuvants for treatment of prostate cancer
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20110003839A1 (en) * 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US20120088767A1 (en) * 2010-10-06 2012-04-12 Junya Qu Benzimidazole derivatives as pi3 kinase inhibitors

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4644737B2 (ja) * 2005-05-13 2011-03-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア ジアリールヒダントイン化合物
PL2538785T3 (pl) * 2010-02-24 2018-08-31 Medivation Prostate Therapeutics Llc Sposoby syntezy zwiazków diarylotiohydantoinowych i diarylohydantoinowych
DK2683694T3 (en) * 2011-03-10 2016-07-18 Suzhou Kintor Pharmaceuticals Inc ANDROGEN RECEPTOR ANTAGONISTS AND APPLICATIONS THEREOF
CN103159680A (zh) * 2011-12-14 2013-06-19 爱美尼迪药物有限公司 咪唑二酮类化合物及其用途
EP2943199A1 (en) * 2013-01-09 2015-11-18 Glaxosmithkline Intellectual Property (No. 2) Limited Combination
SG10201907684PA (en) * 2013-01-15 2019-10-30 Aragon Pharmaceuticals Inc Androgen receptor modulator and uses thereof
AU2014321456B2 (en) * 2013-09-19 2018-05-24 Glaxosmithkline Llc Combination drug therapy

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
US20090175868A1 (en) * 2006-02-03 2009-07-09 Ludwig Dale L IGF-IR antagonists as adjuvants for treatment of prostate cancer
US20110003839A1 (en) * 2006-03-27 2011-01-06 The Regents Of The University Of California Androgen receptor modulator for the treatment of prostate cancer and androgen receptor-associated diseases
US20120088767A1 (en) * 2010-10-06 2012-04-12 Junya Qu Benzimidazole derivatives as pi3 kinase inhibitors

Also Published As

Publication number Publication date
JP6346944B2 (ja) 2018-06-20
RU2016110546A (ru) 2017-10-24
BR112016005000A8 (pt) 2018-01-23
EP3046556A1 (en) 2016-07-27
CA2921156A1 (en) 2015-03-26
KR20160055911A (ko) 2016-05-18
AU2014321456B2 (en) 2018-05-24
JP2016530208A (ja) 2016-09-29
JP2018158930A (ja) 2018-10-11
US20160228446A1 (en) 2016-08-11
WO2015042029A1 (en) 2015-03-26
JP6563558B2 (ja) 2019-08-21
JP2019196391A (ja) 2019-11-14
RU2016110546A3 (https=) 2018-03-20
EP3046556A4 (en) 2017-04-26
AU2014321456A1 (en) 2016-03-10

Similar Documents

Publication Publication Date Title
JP5718929B2 (ja) 組合せ物
CN104530063A (zh) 喹唑啉并杂环类化合物及其制备方法和作为用于治疗癌症的表皮生长因子受体抑制剂的应用
JP2017500307A (ja) がんの処置のためのトラメチニブ、パニツムマブおよびダブラフェニブの組合せ
JP2016503399A (ja) 組合せ
JP6355724B2 (ja) がんを治療するためのアフレセルチブと組み合わせたエンザルタミド
JP6563558B2 (ja) 組み合わせ薬物療法
JP2021155446A (ja) 組合せ物
US20170348329A1 (en) Combination Drug Therapy
HK40081897B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40081897A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40106558A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
JP2017507963A (ja) Ｂｔｋ阻害薬とａｋｔ阻害薬を含む組み合わせ
HK1167287B (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK1167287A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584A (en) Combination comprising an mek inhibitor and a b-raf inhibitor
HK40011584B (en) Combination comprising an mek inhibitor and a b-raf inhibitor

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
AD01 Patent right deemed abandoned

Effective date of abandoning: 20200721